Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 4Leukemia, Biphenotypic, Acute 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neuroblastoma 1Lymphoma 1Hodgkin Disease 1

Interventions

Etoposide 2prednylidene 1deltacortene 1daratumumab 1carmustine, poliferprosan 20 drug combination 1Vincristine 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Plasmablastic Lymphoma × prednylidene × Clear all
NCT04139304 2025-06-29

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

AIDS Malignancy Consortium

Phase EARLY_PHASE1 Recruiting
15 enrolled
Lymphoid

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡